Show simple item record

dc.contributor.authorWang, Yemingen
dc.contributor.authorZhou, Feien
dc.contributor.authorZhang, Dingyuen
dc.contributor.authorZhao, Jianpingen
dc.contributor.authorDu, Ronghuien
dc.contributor.authorHu, Yien
dc.contributor.authorCheng, Zhenshunen
dc.contributor.authorGao, Lingen
dc.contributor.authorJin, Yangen
dc.contributor.authorLuo, Guangweien
dc.contributor.authorFu, Shouzhien
dc.contributor.authorLu, Qiaofaen
dc.contributor.authorDu, Guanhuaen
dc.contributor.authorWang, Keen
dc.contributor.authorLu, Yangen
dc.contributor.authorFan, Guohuien
dc.contributor.authorZhang, Yien
dc.contributor.authorLiu, Yingen
dc.contributor.authorRuan, Shunanen
dc.contributor.authorLiu, Wenen
dc.contributor.authorJaki, Thomasen
dc.contributor.authorHayden, Frederick Gen
dc.contributor.authorHorby, Peter Wen
dc.contributor.authorCao, Binen
dc.contributor.authorWang, Chenen
dc.date.accessioned2020-07-16T23:30:55Z
dc.date.available2020-07-16T23:30:55Z
dc.date.issued2020-05-24en
dc.identifier.issn1745-6215
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/308045
dc.format.mediumElectronicen
dc.languageengen
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectHumansen
dc.subjectPneumonia, Viralen
dc.subjectCoronavirus Infectionsen
dc.subjectAlanineen
dc.subjectAdenosine Monophosphateen
dc.subjectAntiviral Agentsen
dc.subjectTreatment Outcomeen
dc.subjectInfusions, Intravenousen
dc.subjectSeverity of Illness Indexen
dc.subjectRisk Assessmenten
dc.subjectRisk Factorsen
dc.subjectDouble-Blind Methoden
dc.subjectTime Factorsen
dc.subjectChinaen
dc.subjectFemaleen
dc.subjectMaleen
dc.subjectMulticenter Studies as Topicen
dc.subjectClinical Trials, Phase III as Topicen
dc.subjectPandemicsen
dc.subjectPatient Safetyen
dc.subjectBetacoronavirusen
dc.subjectEquivalence Trials as Topicen
dc.subjectCOVID-19en
dc.subjectSARS-CoV-2en
dc.titleEvaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.en
dc.typeArticle
prism.issueIdentifier1en
prism.publicationDate2020en
prism.publicationNameTrialsen
prism.startingPage422
prism.volume21en
dc.identifier.doi10.17863/CAM.55140
dcterms.dateAccepted2020-04-27en
rioxxterms.versionofrecord10.1186/s13063-020-04352-9en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2020-05-24en
dc.contributor.orcidJaki, Thomas [0000-0002-1096-188X]
dc.contributor.orcidHorby, Peter W [0000-0002-9822-1586]
dc.identifier.eissn1745-6215
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idNIHR Academy (NIHRDH-SRF-2015-08-001)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International